Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

References

• Berndt ER, Cockburn IM, Grépin KA. The impact of incremental innovation in biopharmaceuticals. PharmacoEconomics. 2006;24(2):69–86.
   PubMedGoogle Scholar
• Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6(1):14.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Mills E, Mehta C. Global coronavirus COVID-19 clinical trial tracker. https://www.covid19-trials.org. 2020. Accessed 20 Jul 2020.
   Google Scholar
• Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175(2):168–180.
   PubMed Web of Science ®Google Scholar
• Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427–1429.
   PubMed Web of Science ®Google Scholar
• Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021–1026.
   PubMed Web of Science ®Google Scholar
• De Souza JA, Polite B, Perkins M, Meropol NJ, Ratain MJ, Newcomer LN, et al. Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012;12(1):481.
   Google Scholar
• Paczynski RP, Alexander GC, Chinchilli VM, Kruszewski SP. Quality of evidence in drug compendia supporting off-label use of typical and atypical antipsychotic medications. Int J Risk Saf Med. 2012;24:137–146.
   Google Scholar
• McKean A, Monasterio E. Off-label use of atypical antipsychotics. CNS Drugs. 2012;26(5):383–390.
   PubMed Web of Science ®Google Scholar
• Goločorbin-Kon S, Iličković I, Mikov M. Reasons for and frequency of off-label drug use. Med Pregl. 2015;68(1–2):35–40.
   Google Scholar
• Gonçalves MG, Heineck I. Frequency of prescriptions of off-label drugs and drugs not approved for pediatric use in primary health care in a southern municipality of Brazil. Revista Paulista de Pediatria. 2016;34(1):11–17.
   Google Scholar
• Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432. https://doi.org/10.1136/bmj.m1432.
   PubMedGoogle Scholar
• Allen HC, Garbe MC, Lees J, Aziz N, Chaaban H, Miller JL, et al. Off-label medication use in children, more common than we think: a systematic review of the literature. J Okla State Med Assoc. 2018;111(8):776–783.
   PubMedGoogle Scholar
• Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr. 2009;9(2):81–88.
   PubMed Web of Science ®Google Scholar
• Palmaro A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S, et al. Off-label prescribing in pediatric outpatients. Pediatrics. 2015;135(1):49–58.
   PubMed Web of Science ®Google Scholar
• Hoon D, Taylor MT, Kapadia P, Gerhard T, Strom BL, Horton DB. Trends in off-label drug use in ambulatory settings: 2006–2015. Pediatrics. 2019;144:4.
   Web of Science ®Google Scholar
• Federal Food, Dug, and Cosmetic Act 1938 s.505C.3.E and s.505F.J.5 (USA). https://ballotpedia.org/Federal_Food,_Drug,_and_Cosmetic_Act_of_1938. Accessed 1 Feb 2020.
   Google Scholar
• Benjamin N. Roin. Solving the Problem of New Uses. Mich. St. L. Rev; 2013. 67 p. https://dash.harvard.edu/handle/1/11189865. Accessed 10 Jul 2020.
   Google Scholar
• Eisenberg RS. The problem of new uses. Yale J Health Pol’y L & Ethics. 2005;5:717.
   Google Scholar
• Wang B, Liu J, Kesselheim AS. Variations in time of market exclusivity among top-selling prescription drugs in the United States. JAMA Internal Med. 2015;175(4):635–637.
   Web of Science ®Google Scholar
• Grabowski H, Long G, Mortimer R, Boyo A. Updated trends in US brand-name and generic drug competition. J Med Econ. 2016;19(9):836–844.
   PubMed Web of Science ®Google Scholar
• Approved Drug Products with Therapeutic Equivalence Evaluations. The Orange Book. United States Food and Drug Administration. 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book. Accessed 7 Feb 2020.
   Google Scholar
• Drugs@FDA Data Files. Drugs Approvals and Databases. United States Food and Drug Administration. 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files. Accessed 15 Feb 2020.
   Google Scholar
• Richardson E. Off-Label Drug Promotion. Health Affairs. 30 June 2016; doi: https://doi.org/10.1377/hpb20160630.920075
   Google Scholar
• Copenhagen Economics. Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe: Final Report . Publications Office of the European Union. 2018. 386 p.
   Google Scholar
• Sarpatwari A, Beall RF, Abdurrob A, He M, Kesselheim AS. Evaluating the impact of the orphan drug act’s seven-year market exclusivity period. Health Aff. 2018;37(5):732–737.
   Web of Science ®Google Scholar
• Patents and Exclusivity. FDA/CDER SBIA Chronicles. United States Food and Drug Administration. https://www.fda.gov/media/92548/download. Accessed 15 Apr 2020.
   Google Scholar
• Sinha MS, Najafzadeh M, Rajasingh EK, Love J, Kesselheim AS. Labeling changes and costs for clinical trials performed under the US Food and Drug Administration pediatric exclusivity extension, 2007 to 2012. JAMA Internal Med. 2018;178(11):1458–1466.
   Web of Science ®Google Scholar
• Ridley DB, Régnier SA. The commercial market for priority review vouchers. Health Aff. 2016;35(5):776–783.
   Web of Science ®Google Scholar
• Kesselheim AS. Drug development for neglected diseases—the trouble with FDA review vouchers. N Engl J Med. 2008;359(19):1981–1983.
   Web of Science ®Google Scholar